Project Name：Gefitinib

Registration Classification：3+6

Formulations and specifications ：Tablets: 250mg 

Indications：For non-small cell lung cancer (NSCLC) locally advanced or metastatic for patients unsuitable for chemotherapy, also used after failed chemotherapy treatment 

Original Research Company：A company AstraZeneca 

Progress ：Pharmaceutical Research in progress